New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
07:25 EDTAGN, SHPG, VRX, JAZZ, ALKSAllergan approached Shire about potential takeover months ago, Reuters says
Allergan (AGN) reportedly approached Shire (SHPG) several months ago about a possible takeover, Reuters reports, though initial conversations never turned into more serious discussions. Since then, Allergan has received an unsolicited $47B offer from Valeant (VRX) and Pershing Square. It is unclear whether Allergan will look to revive talks with Shire or pursue another acquisition target like Jazz (JAZZ) or Alkermes (ALKS). Reference Link
News For AGN;SHPG;VRX;JAZZ;ALKS From The Last 14 Days
Check below for free stories on AGN;SHPG;VRX;JAZZ;ALKS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 10, 2014
07:06 EDTSHPGSangamo plans to submit IND application for hemophilia B in 2Q15
Sangamo BioSciences (SGMO) plans to submit an Investigational New Drug application for the treatment of hemophilia B in Q2 2015. This program, partnered with Shire (SHPG), is the first therapeutic application of Sangamo's zinc finger nuclease-mediated In Vivo Protein Replacement Platform. Sangamo is developing the IVPRP as a generally applicable strategy to provide a one-time, permanent genetic cure for monogenic diseases that are currently managed by protein replacement therapy, which involves costly repeat infusions over the lifetime of the patient.
September 9, 2014
16:04 EDTAGNPershing Square reports 9.7% stake in Allergan, sends letter to board
Pershing Square Capital Management sent a letter to the board of Allergan that highlights several reasons why Allergan is extremely shareholder unfriendly and why now is the time for Allergan's management team to wake up. In the letter, Pershing Square said: "Since the bid was announced in April, 75% of Allergan’s shareholders have sold all or a portion of their investment including the company’s largest shareholder, which has sold its entire position. These shareholders are sending the board a message. They would not have sold if they believed that Allergan stock was worth more than current values... We note CFO Jeff Edwards recent decision to retire from the company at age 53 for family reasons, and his replacement by an investor relations executive rather than an experienced public company CFO. The notion that Allergan should execute the largest acquisition in its history led by an investor relations executive is a frightening proposition. While we respect an executive’s need to retire from a company for family reasons, Edwards exit also calls into question the company’s forward earnings guidance which shareholders expected him to execute on when the Company presented these projections on July 21st. I had expected that at some point one or more directors would have woken up and smelled the coffee. There is still time for a subset of directors to rescue their reputations by taking over leadership of this process from David Pyott and his handpicked advisors and doing what you are paid $400,000 per year to do on behalf of the company’s owners."
06:51 EDTALKSAlkermes management to meet with Leerink
Subscribe for More Information
06:42 EDTVRX, AGNLew expects to make decision on combating inversion deals soon, NY Times reports
Subscribe for More Information
September 8, 2014
17:01 EDTVRXValeant to expand Bausch + Lomb facility, will add 120 new jobs
Valeant Pharmaceuticals announced that the company hosted a ribbon cutting ceremony for the new Bausch + Lomb ULTRA contact lens manufacturing lines and solar array assembly at the company's Optics Center in Rochester, NY. The ceremony recognized the expansion and installation of the new manufacturing lines, which will produce the company's silicone hydrogel contact lens, Bausch + Lomb ULTRA. The solar array, which is currently under construction, will generate and supply electricity through the installation of 3,667 solar panels, helping to reduce the Rochester facility's carbon footprint by 800 tons of carbon dioxide emissions annually.
08:17 EDTJAZZJazz Pharmaceuticals executing on all cylinders, says Stifel
Following management meetings, Stifel reiterates its Buy rating and $195 price target on Jazz Pharmaceuticals given growth opportunities and sustainability of its current portfolio. The firm agrees with the Xyrem franchise expansion strategies through new patient capture near-term, and longer-term, the addition of complementary wakefulness products.
07:21 EDTJAZZ, AGNJazz looks more attractive for Allergan than Salix, says Wells Fargo
Subscribe for More Information
September 5, 2014
11:40 EDTJAZZJazz Pharmaceuticals calls active on renewed takeover speculation
Subscribe for More Information
11:00 EDTJAZZRumor: Jazz Pharmaceuticals strength attributed to renewed takeover speculation
Subscribe for More Information
10:05 EDTVRX, AGNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) initiated with a Buy at ISI Group... Akamai (AKAM) initiated with a Buy at UBS... Alexion (ALXN) initiated with a Buy at SunTrust... Allegion (ALLE) initiated with a Buy at Buckingham... Allergan (AGN) initiated with a Buy at ISI Group... Aviat Networks (AVNW) initiated with a Neutral at H.C. Wainwright... Celgene (CELG) initiated with a Buy at SunTrust... EZCORP (EZPW) initiated with a Hold at Jefferies... Eaton (ETN) initiated with a Neutral at Buckingham... Emerson (EMR) initiated with a Neutral at Buckingham... HMS Holdings (HMSY) initiated with an Overweight at Stephens... Incyte (INCY) initiated with a Buy at SunTrust... Ingersoll-Rand (IR) initiated with a Neutral at Buckingham... Insmed (INSM) initiated with an Outperform at Cowen... Intercept (ICPT) initiated with an Outperform at Cowen... Johnson & Johnson (JNJ) initiated with an Outperform at BMO Capital... Lennox (LII) initiated with a Neutral at Buckingham... Mylan (MYL) initiated with a Hold at ISI Group... Orion Engineered Carbons (OEC) initiated with a Buy at Goldman... Parker-Hannifin (PH) initiated with a Buy at Buckingham... Pentair (PNR) initiated with a Neutral at Buckingham... Pharmacyclics (PCYC) initiated with a Neutral at SunTrust... Rockwell Automation (ROK) initiated with a Neutral at Buckingham... Sabre (SABR) initiated with an Outperform at Oppenheimer... Santander Consumer (SC) initiated with a Buy at Jefferies... Springleaf (LEAF) initiated with a Buy at Jefferies... Susser Petroleum (SUSP) initiated with a Neutral at Credit Suisse... Teva (TEVA) initiated with a Buy at ISI Group... Valeant (VRX) initiated with a Buy at ISI Group... WESCO (WCC) initiated with a Neutral at Buckingham... Watsco (WSO) initiated with a Neutral at Buckingham... Weyerhaeuser (WY) initiated with a Neutral at JPMorgan... World Acceptance (WRLD) initiated with a Hold at Jefferies.
September 4, 2014
19:12 EDTAGNAllergan provides update on requests from Pershing regarding special meeting
Subscribe for More Information
17:17 EDTAGNAllergan initiated with a Buy at ISI Group
Subscribe for More Information
17:16 EDTVRXValeant initiated with a Buy at ISI Group
Target $159.
09:44 EDTAGN, VRXValeant, Ackman deliver another 2.8% consent vote to Allergan, CNBC reports
Valeant (VRX) and Bill Ackman delivered another 2.8% consent vote to Allergan, bringing its total vote to call a special meeting to 33.8%, CNBC's David Faber reports, citing sources. A special meeting has been set for December 18, Faber added.
September 3, 2014
12:19 EDTSHPGOptions with increasing implied volatility
Subscribe for More Information
07:47 EDTJAZZJazz Pharmaceuticals management to meet with Deutsche Bank
Subscribe for More Information
07:05 EDTALKSAlkermes completes patient enrollment in Phase 2 ALKS 3831 study
Subscribe for More Information
September 2, 2014
09:07 EDTAGN, VRXAllergan filed answer in federal court reponding to Valeant, Pershing claims
Subscribe for More Information
08:05 EDTAGNAllergan says Ozurdex apporved in EU for treatment of diabetic macular edema
Subscribe for More Information
07:12 EDTALKSCredit Suisse names its Top U.S. Pharmaceutical picks for 2H
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use